血清HBV RNA的基线和动力学预测HBeAg阴性慢性乙型肝炎患者对

StephenW

Journal Summaries in Infectious Disease
Baseline and kinetics of serum HBV RNA predict response to pegylated interferon-based therapy in patients with HBeAg-negative chronic hepatitis B

Journal of Viral Hepatitis — Limothai U, Chuaypen N, Poovorawan K, et al. | August 29, 2019

Researchers examined the role of serum hepatitis B virus (HBV) RNA in predicting long-term outcome of patients with HBeAg(hepatitis B e antigen)-negative chronic hepatitis B (CHB) receiving pegylated interferon (PEG-IFN)-based therapy. They retrospectively analyzed serial serum samples from 91 patients with HBeAg-negative CHB previously treated with PEG-IFN alone or combined with entecavir in a randomized trial. Outcomes revealed a correlation of baseline serum HBV RNA concentrations with HBV DNA and covalently closed circular DNA but with HBsAg (hepatitis B surface antigen) levels. As per multiple regression analysis, there was an independent correlation of pretreatment HBV RNA and HBsAg with maintained virological response [MVR (maintained virological response), HBV DNA < 2,000 IU/mL] and HBsAg clearance. Findings here support the value of determining HBV RNA prior to PEG-IFN-based therapy for identifying patients with high probability of MVR. Further, HBV RNA kinetics seem to be valuable as a promising ‘stopping rule’ in patients infected with HBV genotypes B or C.

StephenW

传染病杂志综述
血清HBV RNA的基线和动力学预测HBeAg阴性慢性乙型肝炎患者对聚乙二醇干扰素治疗的反应

病毒性肝炎杂志 -  Limothai U，Chuaypen N，Poovorawan K，et al。 | 2019年8月29日

研究人员检测了血清乙型肝炎病毒（HBV）RNA在预测接受聚乙二醇化干扰素（PEG-IFN）治疗的HBeAg（乙型肝炎e抗原）阴性慢性乙型肝炎（CHB）患者的长期预后中的作用。他们回顾性分析了91例HBeAg阴性CHB患者的系列血清样本，这些患者之前用PEG-IFN单独或与恩替卡韦联合进行随机试验。结果显示基线血清HBV RNA浓度与HBV DNA和共价闭合环状DNA相关，但与HBsAg（乙型肝炎表面抗原）水平相关。根据多元回归分析，治疗前HBV RNA和HBsAg与维持的病毒学应答[MVR（维持病毒学应答），HBV DNA <2,000 IU / mL]和HBsAg清除率存在独立相关性。这里的发现支持在基于PEG-IFN的疗法之前确定HBV RNA的价值，以鉴定具有高MVR概率的患者。此外，HBV RNA动力学似乎是有价值的，因为感染HBV基因型B或C的患者有希望的“停止规则”。

StephenW

https://onlinelibrary.wiley.com/ ... WtFuvWtoxgGAw%3D%3D